2024-10-09 - Analysis Report
## Gilead Sciences Inc (GILD) Stock Analysis Report

**Company Overview:** Gilead Sciences Inc. is a biopharmaceutical company that researches, develops, and commercializes drugs for the treatment of life-threatening diseases.

**Performance Metrics:**

**1. Relative Performance:**

* **Cumulative Return:** -12.26% (GILD) vs. 133.14% (S&P 500, VOO)
* **Relative Deviation:** -145.4 (Current), 6.43% (Relative)
* **Interpretation:** GILD has significantly underperformed the S&P 500 over the period, lagging behind by a substantial margin. This underperformance is evident in its relative deviation, which is a measure of its distance from the S&P 500's cumulative return.

**2. Recent Price Movements:**

* **Closing Price:** 84.59
* **5-Day Moving Average:** 84.26
* **20-Day Moving Average:** 83.22
* **60-Day Moving Average:** 77.96
* **Interpretation:** The stock price is currently trading slightly above its 5-day moving average, suggesting some short-term upward momentum. The price is also above both the 20-day and 60-day moving averages, indicating potential for continued upward movement in the medium to long term.

**3. Technical Indicators:**

* **RSI:** 59.2 (Neutral)
* **PPO:** -0.24 (Bearish)
* **Relative Divergence (20 days):** -4.28 (Short-term decline)
* **Expected Return:** 0.0% (5-year estimated return over S&P 500)
* **Interpretation:** The RSI indicates a neutral sentiment, with the stock not currently overbought or oversold. The negative PPO suggests a bearish trend, indicating potential for further downside movement. The short-term decline in relative divergence supports the bearish trend.

**4. Recent Earnings & Outlook:**

| Date | EPS | Revenue |
|---|---|---|
| 2024-08-08 | 1.29 | 6.95 B$ |
| 2024-05-08 | -3.34 | 6.69 B$ |
| 2023-11-07 | 1.75 | 7.05 B$ |
| 2023-08-04 | 0.84 | 6.60 B$ |
| 2024-08-08 | 0.84 | 6.60 B$ |

* **Interpretation:** Gilead's most recent earnings report (2024-08-08) reported an EPS of 1.29, exceeding analysts' estimates. Revenue also slightly surpassed expectations. However, the company has faced challenges in recent quarters, with fluctuating performance. 

**5. News and Recent Issues:**

* **Recent Market Outlook:** Gilead is facing headwinds from generic competition for its flagship HIV drug, Biktarvy, and potential revenue declines in the coming years. However, the company is actively pursuing new treatments in areas like cell therapy and oncology.
* **Analyst Opinions:** While analysts generally maintain a neutral outlook on Gilead, there is a range of opinions, with some expecting a modest recovery while others remain cautious. 
* **Performance Highlights:** Gilead's core HIV business remains strong, but the company is facing pressure to diversify its portfolio and develop new growth drivers.

**6. Summary:**

Gilead Sciences has experienced significant underperformance relative to the S&P 500. While its recent earnings exceeded expectations, the company faces headwinds from generic competition and is actively pursuing new growth opportunities. Technical indicators suggest a bearish trend, with potential for further downside movement in the short term. However, the stock price remains above its long-term moving averages, indicating potential for a rebound in the medium to long term. 

**7. Overall, Gilead's future performance will depend on its ability to successfully diversify its portfolio, manage generic competition, and develop new growth drivers. Investors should closely monitor the company's progress in these areas.**
